On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research entry: inclusion is for identification, not approval or a recommendation to use it. Verify the exact product and current US status with a pharmacist.
What the evidence shows
What the cited report actually studied
The knee-pain report described BPC-157 with TB4 in a small subgroup. It does not validate every marketed BPC-157/TB-500 blend or demonstrate that combining them is better. [1]
A blend is a separate evidence question
Full-length thymosin beta-4 has been studied in eye drops. That study does not evaluate this blend, the TB-500 fragment, or whether adding it to BPC-157 improves an outcome. The presence of two researched ingredients does not prove a researched combination. [2]
What remains unknown
Combined efficacy, interactions, and product consistency are not established by this report.
Safety
Safety uncertainty
Human safety information is limited. FDA flags immune-reaction and impurity concerns for this substance. [3]
The studied combination was not a universal recipe
The knee report describes particular intra-articular preparations. It does not establish a composition, route, stability, or shelf life for every product marketed under this blend name. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does a combination work better than either ingredient?
The cited evidence cannot answer that. Demonstrating an additional benefit needs an appropriate comparison, and interaction risks need their own assessment.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain2021 · retrospective human study · PMID 34324435
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model2015 · randomized eye-drop trial · 72 participants
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · safety information · accessed September 2026
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.